What analysts say:
- Buy, sell, or hold?: Analysts strongly back ViroPharma, with 12 of 15 rating it a buy and the remainder rating it a hold. Analysts still rate the stock a moderate buy, but they are a bit more wary about it compared to three months ago.
- Revenue forecasts: On average, analysts predict $129.5 million in revenue this quarter. That would represent a rise of 9.9% from the year-ago quarter.
- Wall Street earnings expectations: The average analyst estimate is earnings of $0.32 per share. Estimates range from $0.21 to $0.41.
What our community says:
CAPS All-Stars are solidly behind the stock with 97.7% assigning it an "outperform" rating. The community at large concurs with the All-Stars with 97.2% awarding it a rating of "outperform." Fools are bullish on ViroPharma and haven't been shy with their opinions lately, logging 464 posts in the past 30 days. Even with a robust four out of five stars, ViroPharma's CAPS rating falls a little short of the community's upbeat outlook.
ViroPharma's profit has risen year over year by an average of 88.5% over the past five quarters. The company's gross margin shrank by four percentage points in the last quarter. Revenue rose 18.2% while cost of sales rose 56.2% to $21.3 million from a year earlier.
One final thing: If you want to keep tabs on ViroPharma movements, and for more analysis on the company, make sure you add it to your Watchlist.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
A Look Back at Halozyme's Volatile but Rewarding 2013
As 2013 draws to a close, let’s take a look back at Halozyme’s volatile performance throughout the year and review its key collaborations with ViroPharma (Shire), Roche, Baxter, and Pfizer.
3 Surging Biotechs That Made Investors Rich in November
ViroPharma, Idenix, and Geron all boomed in a big way for shareholders over the past month.
3 Humongous Health-Care Stocks This Week
Vanda, Organovo, and Cadence scored the biggest health-care wins this week. But ViroPharma wasn't too far behind.